Martin Rowe

List of Publications by Year in Descending Order

150 papers	12,381 citations	62 h-index	109 g-index
153 ext. papers	13,011 ext. citations	9 avg, IF	5.57 L-index

#	Paper	IF	Citations
150	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. *Cell Death and Differentiation*, **2020**, 27, 1554-1568	12.7	12
149	Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. *Leukemia*, **2019**, 33, 2884-2897	10.7	11
148	Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells. *Cell Death and Differentiation*, **2018**, 25, 241-254	12.7	13
147	The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. *Journal of Virology* , **2016**, 90, 356-67	6.6	40
146	Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle. *Journal of Virology*, **2016**, 90, 947-58	6.6	19
145	Immunity to Oncogenic Viruses **2016**, 363-374		
144	The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation. *Journal of Virology*, **2015**, 89, 2483-93	6.6	3
143	Innate Immune Recognition of EBV. *Current Topics in Microbiology and Immunology*, **2015**, 391, 265-87	3.3	17
142	Epstein-Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. *Nucleic Acids Research*, **2015**, 43, 3563-77	20.1	28
141	Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. *Blood*, **2015**, 126, 2665-75	2.2	25
140	Identification of Epstein-Barr Virus Replication Proteins in Burkitt's Lymphoma Cells. *Pathogens*, **2015**, 4, 739-51	4.5	13
139	Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. *Virology*, **2015**, 474, 117-30	3.6	55
138	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. *Genes and Development*, **2014**, 28, 58-70	12.6	121
137	Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. *Journal of Virology*, **2014**, 88, 12065-76	6.6	26
136	Epstein Barr virus entry; kissing and conjugation. *Current Opinion in Virology*, **2014**, 4, 78-84	7.5	45
135	Epstein-Barr virus and Burkitt lymphoma. *Chinese Journal of Cancer*, **2014**, 33, 609-19		40
134	Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. *PLoS Pathogens*, **2014**, 10, e1004322	7.6	33

133	Suppression of the LMP2A target gene, EGR-1, protects Hodgkin lymphoma cells from entry to the EBV lytic cycle. *Journal of Pathology*, **2013**, 230, 399-409	9.4	27
132	Kaposi sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis. *Journal of Virology*, **2013**, 87, 5340-50	6.6	16
131	Induction of interferon-stimulated genes on the IL-4 response axis by Epstein-Barr virus infected human b cells; relevance to cellular transformation. *PLoS ONE*, **2013**, 8, e64868	3.7	9
130	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*, **2012**, 490, 116-20	50.4	600
129	Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. *Current Hematologic Malignancy Reports*, **2012**, 7, 276-84	4.4	23
128	Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas. *Pathogens*, **2012**, 1, 83-101	4.5	10
127	Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin Lymphoma. *Pathogens*, **2012**, 1, 52-64	4.5	9
126	Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway. *Viruses*, **2012**, 4, 1335-53	6.2	21
125	Down-regulation of BLIMP1 by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. *Blood*, **2011**, 117, 5907-17	2.2	76
124	The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin Lymphoma. *Oncogene*, **2011**, 30, 2037-43	9.2	112
123	Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. *Herpesviridae*, **2011**, 2, 8		33
122	The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. *Journal of Virology*, **2011**, 85, 1604-14	6.6	58
121	Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. *Journal of Virology*, **2011**, 85, 996-1010	6.6	87
120	Epstein-Barr virus latent membrane protein 1 increases calcium influx through store-operated channels in B lymphoid cells. *Journal of Biological Chemistry*, **2011**, 286, 18583-92	5.4	24
119	Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin lymphoma. *Journal of Virology*, **2011**, 85, 9568-77	6.6	72
118	Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. *PLoS Pathogens*, **2011**, 7, e1001338	7.6	78
117	Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2. *PLoS Pathogens*, **2011**, 7, e1002455	7.6	51
116	Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. *Clinical Infectious Diseases*, **2010**, 51, 66-9	11.6	44

115	A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. *Blood*, **2010**, 116, 3695-704	2.2	54
114	Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. *Microbes and Infection*, **2010**, 12, 173-81	9.3	39
113	Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. *PLoS Pathogens*, **2009**, 5, e1000490	7.6	68
112	Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. *Journal of Virology*, **2009**, 83, 7749-60	6.6	92
111	An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. *PLoS Pathogens*, **2009**, 5, e1000341	7.6	128
110	STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells. *Journal of General Virology*, **2009**, 90, 2239-50	4.9	8
109	Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. *Journal of Immunology*, **2009**, 182, 1919-28	5.3	26
108	The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. *PLoS Pathogens*, **2009**, 5, e1000255	7.6	124
107	Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. *Seminars in Cancer Biology*, **2009**, 19, 377-88	12.7	80
106	Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus latent membrane protein-1. *Molecular Cancer*, **2009**, 8, 59	42.1	27
105	Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. *Seminars in Cancer Biology*, **2008**, 18, 397-408	12.7	94
104	The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. *Journal of Virology*, **2008**, 82, 2385-93	6.6	79
103	Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 3366-71	11.5	172
102	CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells. *Journal of Immunology*, **2007**, 179, 2705-12	5.3	12
101	Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. *Journal of General Virology*, **2007**, 88, 1876-1886	4.9	14
100	The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. *Journal of Virology*, **2007**, 81, 474-82	6.6	112
99	Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. *Blood*, **2007**, 109, 2597-603	2.2	76
98	Three Restricted Forms of Epstein-Barr Virus Latency Counteracting Apoptosis in c-Myc Expressing Burkitt Lymphoma Cells.. *Blood*, **2007**, 110, 1572-1572	2.2	2

97	Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. *Journal of Virology*, **2006**, 80, 11191-9	6.6	22
96	Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. *Journal of Virology*, **2005**, 79, 841-52	6.6	68
95	Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. *Journal of Immunology*, **2005**, 174, 6829-38	5.3	57
94	Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression. *Journal of General Virology*, **2005**, 86, 1669-1679	4.9	13
93	Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. *Journal of Virology*, **2004**, 78, 1800-16	6.6	47
92	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. *FEBS Letters*, **2004**, 570, 138-42	3.8	6
91	Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. *Journal of Biological Chemistry*, **2003**, 278, 46565-75	5.4	60
90	Epstein-Barr Virus Latent Membrane Protein-1 Mediates Upregulation of Tumor Necrosis Factor-α in EBV-Infected T Cells: Implications for the Pathogenesis of Hemophagocytic Syndrome. *Journal of Biomedical Science*, **2003**, 10, 146-155	13.3	13
89	Epstein-Barr virus regulates STAT1 through latent membrane protein 1. *Journal of Virology*, **2003**, 77, 4439-43	6.6	22
88	Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-alpha in EBV-infected T cells: implications for the pathogenesis of hemophagocytic syndrome. *Journal of Biomedical Science*, **2003**, 10, 146-55	13.3	10
87	NF-kappaB is required for cell death induction by latent membrane protein 1 of Epstein-Barr virus. *Cellular Signalling*, **2003**, 15, 423-33	4.9	12
86	Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. *Journal of Biological Chemistry*, **2003**, 278, 51134-42	5.4	64
85	Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. *Journal of Cell Biology*, **2003**, 162, 173-83	7.3	73
84	Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. *Journal of Virology*, **2003**, 77, 5000-7	6.6	55
83	Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. *Oncogene*, **2002**, 21, 1263-71	9.2	52
82	Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. *Journal of Virology*, **2002**, 76, 4699-708	6.6	79
81	The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. *Journal of Virology*, **2002**, 76, 8179-88	6.6	63
80	CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB. *Blood*, **2001**, 97, 3596-604	2.2	19

79	Cell transformation induced by Epstein-Barr virus--living dangerously. *Seminars in Cancer Biology*, **2001**, 11, 403-5	12.7	6
78	Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. *Journal of Virology*, **2001**, 75, 9129-41	6.6	60
77	Mechanism of action of a novel latent membrane protein-1 dominant negative. *Journal of Biological Chemistry*, **2001**, 276, 1195-203	5.4	44
76	Characterization of a CD40-dominant inhibitory receptor mutant. *Journal of Immunology*, **2001**, 167, 6388-93	5.3	3
75	Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription. *Journal of Biological Chemistry*, **2001**, 276, 984-92	5.4	36
74	Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. *Journal of Immunology*, **2001**, 167, 5420-8	5.3	88
73	Detection of EBV latent proteins by western blotting. *Methods in Molecular Biology*, **2001**, 174, 229-42	1.4	4
72	Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin and Reed-Sternberg phenotype. *Blood*, **2000**, 95, 294-300	2.2	64
71	The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt lymphoma cell line. *Journal of Virology*, **2000**, 74, 6652-8	6.6	78
70	Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin and Reed-Sternberg phenotype. *Blood*, **2000**, 95, 294-300	2.2	2
69	Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. *Journal of Virology*, **1999**, 73, 1023-35	6.6	168
68	Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. *Journal of Virology*, **1999**, 73, 5688-97	6.6	131
67	Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. *Oncogene*, **1998**, 17, 2383-92	9.2	53
66	Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-Virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin lymphoma. *International Journal of Cancer*, **1998**, 76, 194-200	7.5	18
65	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. *Seminars in Immunopathology*, **1998**, 20, 389-403		15
64	The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. *Journal of Virology*, **1998**, 72, 4038-48	6.6	44
63	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders **1998**, 20, 389		1
62	Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. *Journal of Experimental Medicine*, **1997**, 186, 1575-83	16.6	65

61	Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. *Oncogene*, **1997**, 14, 2899-916	9.2	231
60	Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. *Oncogene*, **1997**, 15, 1851-8	9.2	105
59	Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. *Virology*, **1996**, 223, 29-40	3.6	122
58	Lymphoblastoid cells transfected with c-myc: downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro. *International Journal of Cancer*, **1996**, 68, 810-6	7.5	7
57	The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. *Nature Medicine*, **1995**, 1, 464-70	50.5	166
56	Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. *Journal of Experimental Medicine*, **1995**, 181, 2221-8	16.6	83
55	Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. *European Journal of Immunology*, **1995**, 25, 1374-84	6.1	175
54	The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. *Journal of General Virology*, **1995**, 76 (Pt 4), 779-90	4.9	46
53	Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. *Journal of General Virology*, **1994**, 75 (Pt 4), 769-78	4.9	48
52	Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. *European Journal of Immunology*, **1994**, 24, 1879-85	6.1	41
51	HIV-1 induces down-regulation of bcl-2 expression and death by apoptosis of EBV-immortalized B cells: a model for a persistent "self-limiting" HIV-1 infection. *Virology*, **1994**, 198, 234-44	3.6	38
50	Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines. *Virology*, **1994**, 199, 339-53	3.6	12
49	Epstein-Barr virus transforming proteins. *Seminars in Virology*, **1994**, 5, 391-399		10
48	PATTERNS OF EPSTEIN-BARR VIRUS LATENT AND REPLICATIVE GENE EXPRESSION IN EPSTEIN-BARR VIRUS B CELL LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION. *Transplantation*, **1994**, 58, 317-323	1.8	66
47	Cytogenetic rearrangement of C-MYC oncogene occurs prior to infection with Epstein-Barr virus in the monoclonal malignant B cells from an AIDS patient. *Leukemia and Lymphoma*, **1993**, 9, 157-64	1.9	11
46	MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. *International Immunology*, **1993**, 5, 451-60	4.9	10
45	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. *Science*, **1993**, 260, 98-100	33.3	242
44	Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 8479-83	11.5	513

43	Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. *Journal of Experimental Medicine*, **1992**, 176, 157-68	16.6	441
42	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. *Diagnostic Molecular Pathology*, **1992**, 1, 103-108		49
41	Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. *Journal of Pathology*, **1992**, 166, 1-5	9.4	115
40	Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. *Virology*, **1992**, 187, 189-201	3.6	106
39	Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. *European Journal of Immunology*, **1992**, 22, 1741-8	6.1	3
38	Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. *Journal of Pathology*, **1991**, 165, 289-99	9.4	93
37	Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. *Journal of Experimental Medicine*, **1991**, 173, 147-58	16.6	261
36	The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. *Journal of General Virology*, **1991**, 72 (Pt 7), 1579-90	4.9	88
35	Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. *Lancet, The*, **1991**, 337, 320-2	40	621
34	Epstein-Barr virus latent genes in tumour cells of Hodgkin's disease. *Lancet, The*, **1991**, 337, 1617	40	12
33	Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell*, **1991**, 65, 1107-15	56.2	1041
32	Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 6343-7	11.5	137
31	Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells. *European Journal of Immunology*, **1990**, 20, 659-64	6.1	7
30	Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. *International Journal of Cancer*, **1990**, 45, 77-82	7.5	20
29	Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules. *International Journal of Cancer*, **1990**, 45, 299-307	7.5	10
28	Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 2906-10	11.5	92
27	Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. *Journal of General Virology*, **1990**, 71 (Pt 7), 1481-95	4.9	291
26	EBV, molecular mimicry and rheumatoid arthritis: a hypothesis. *Immunology Letters*, **1989**, 20, 93	4.1	

25	The Epstein-Barr virus:host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. *International Journal of Cancer*, **1989**, 43, 61-6	7.5	43
24	Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. *International Journal of Cancer*, **1989**, 43, 67-71	7.5	147
23	Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. *International Journal of Cancer*, **1988**, 42, 213-20	7.5	38
22	Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. *International Journal of Cancer*, **1988**, 42, 329-38	7.5	394
21	Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. *Journal of General Virology*, **1988**, 69 (Pt 6), 1217-28	4.9	33
20	Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. *Journal of General Virology*, **1987**, 68 (Pt 6), 1575-86	4.9	241
19	Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 3452-6	11.5	330
18	Epstein-Barr virus-specific T-cell recognition of B-cell transformants expressing different EBNA 2 antigens. *International Journal of Cancer*, **1987**, 39, 373-9	7.5	8
17	The level of expression of class-I MHC antigens in adenovirus-transformed human cell lines. *International Journal of Cancer*, **1987**, 40, 213-9	7.5	9
16	Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. *European Journal of Immunology* , **1987**, 17, 1199-207	6.1	64
15	Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt lymphoma. *International Journal of Cancer*, **1986**, 37, 367-73	7.5	84
14	Ligation of the CD23,p45 (BLAST-2,EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. *European Journal of Immunology*, **1986**, 16, 1075-80	6.1	109
13	Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor. *European Journal of Immunology*, **1986**, 16, 1627-30	6.1	92
12	Burkitt-like lymphoma in an English child: characterisation of tumour biopsy cells and of the derived tumour cell line. *British Journal of Cancer*, **1986**, 54, 385-91	8.7	4
11	Epstein-Barr virus-positive Burkitt lymphoma cells not recognized by virus-specific T-cell surveillance. *Nature*, **1985**, 317, 629-31	50.4	131
10	Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt lymphoma. *International Journal of Cancer*, **1985**, 35, 435-41	7.5	110
9	T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. *Cellular Immunology*, **1984**, 87, 646-58	4.4	123
8	Selective reactivation of Epstein-Barr virus-specific cytotoxic T cells by stimulation in vitro with allogeneic virus-transformed HLA-homozygous typing cells. *Human Immunology*, **1983**, 6, 151-65	2.3	4

7	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. I. Virus-specific and nonspecific components of the cytotoxic response. *Cellular Immunology*, **1982**, 67, 129-40	4.4	54
6	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. II. Cytotoxic response to repeated stimulation. *Cellular Immunology*, **1982**, 67, 141-51	4.4	11
5	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. *European Journal of Immunology*, **1982**, 12, 1012-8	6.1	60
4	Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. *International Journal of Cancer*, **1982**, 29, 373-81	7.5	135
3	Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. *Nature*, **1982**, 297, 413-5	50.4	98
2	Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. *International Journal of Cancer*, **1981**, 27, 593-601	7.5	64
1	Human lymphocyte ecto-5Pnucleotidase is not directly involved in immunoglobulin production [proceedings]. *Biochemical Society Transactions*, **1979**, 7, 997-8	5.1	2